C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma



Status:Completed
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 90
Updated:3/9/2019
Start Date:April 2012
End Date:January 2019

Use our guide to learn which trials are right for you!

Positron emission tomography using carbon-11 acetate (AC-PET) may help find local or distant
metastases from prostate cancer. This clinical trial is studying how this imaging test may
help influence the choice and extent of initial treatments, and subsequent treatments.

OBJECTIVES:

- Determine the role of positron emission tomography using carbon-11 acetate (AC-PET) in
the initial and subsequent management of patients with prostate cancer at intermediate
or high risk for recurrence after initial curative therapy.

- Compare the value of AC-PET in predicting recurrence of prostate cancer with that of
conventional approaches (e.g., pre-operative clinical staging, prostate-specific
antigen, Gleason score, prostate and lymph node histology) in these patients.

Inclusion Criteria:

Male patients will be studied who have prostate cancer:

- Diagnosed with prostate adenocarcinoma

- Has completed conventional staging examinations, including histologic evaluation with
Gleason score, CT scan of the abdomen and pelvis, and whole-body bone scintigraphy
Candidate for curative prostatectomy OR curative radiotherapy OR staging
lymphadenectomy prior to surgery

- Deemed to be at intermediate or high risk for recurrence or metastatic disease after
initial curative treatment, as defined by of one of the following:

- Gleason score >= 7 or PSA >= 10

- Gleason score < 7 or PSA <10 ng/mL with positive surgical margins, biopsy proven
or suspected regional nodal involvement or conventional imaging showing limited
metastatic disease that may be amenable to directed radiotherapy

- Rising or non-responding PSA

Exclusion Criteria:

- < 18 years old

- claustrophobic patients
We found this trial at
1
site
Phoenix, Arizona 85040
Principal Investigator: Fabio Almeida, MD
Phone: 520-661-5125
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials